Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: J Clin Gastroenterol. 2021 May 28;56(7):627–634. doi: 10.1097/MCG.0000000000001558

FIGURE 1.

FIGURE 1.

A landmark analysis design featuring the IMS Pharmetrics database was performed. This methods overview includes the assessment of: (1) exposure to prescription anticoagulants, antiplatelets, NSAIDs, and (2) outcomes including any bleeding or portal hypertension decompensation events. GI indicates gastrointestinal; HTN, hypertension; NSAID, nonsteroidal anti-inflammatory drug.